treatments

Newer, more potent therapies offer greater benefit than standard immunosuppressants in reducing relapse rates for people who develop neuromyelitis optica spectrum disorder (NMOSD) after the age of 50, according to a large, single-center study in China. While people with late-onset NMOSD experienced more severe symptoms at onset and during…

Neuromyelitis optica spectrum disorder (NMOSD) is largely known for its effect on the central nervous system, but the associated skin issues are often overlooked. For those of us living with NMOSD, the skin can become a silent messenger, reflecting the internal battle happening within our body. From goose…

Nearly all neuroimmunologists treating patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies have prescribed one of the three currently approved therapies: Soliris (eculizumab), Uplizna (inebilizumab-cdon), and Enspryng (satralizumab-mwge). These are the findings of a U.S. survey that also found most responding…

We all want to belong, but having a rare disease can sometimes feel lonely. Thankfully, the neuromyelitis optica (NMO) community has come a long way since I was diagnosed over 13 years ago. I’ve come a long way, too. Acknowledging that March is NMO Awareness Month is a…

The Sumaira Foundation (TSF) seeks to raise $250,000 for research into neuromyelitis optica spectrum disorder (NMOSD) and related disorders at its 5th NMO Awareness Gala, set for March 26. The Hollywood-themed event will be held at the Mandarin Oriental hotel in Boston. For ballroom entry, all attendees must…